Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine, Inc. (NASDAQ: IRON) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its clinical-stage biopharmaceutical business focused on serious hematologic diseases. These SEC filings cover financial results, capital-raising transactions, regulatory milestones, and key corporate events related to the company’s investigational programs in red blood cell biology, heme biosynthesis, and iron homeostasis.
Among the most frequently referenced documents are current reports on Form 8-K, where Disc Medicine discloses material events such as quarterly financial results, public offerings of common stock and pre-funded warrants, and significant regulatory developments. For example, the company has used 8-K filings to report a Commissioner’s National Priority Voucher from the U.S. Food and Drug Administration for bitopertin in erythropoietic protoporphyria, the submission of a New Drug Application under the accelerated approval pathway, and the terms of an underwriting agreement for an upsized public offering intended to support operations and development plans.
Investors also look to Disc Medicine’s periodic reports on Forms 10-K and 10-Q for comprehensive discussions of its pipeline, including bitopertin, DISC-0974, and DISC-3405, as well as risk factors and management’s analysis of financial condition. Filings may describe clinical trial status, patent coverage such as composition of matter protection for DISC-0974, and the company’s expectations regarding cash runway based on existing cash, cash equivalents, marketable securities, and offering proceeds.
On this page, users can access Disc Medicine’s SEC filings as they are made available through EDGAR. AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as clinical development, financing terms, and forward-looking statements, and make it easier to understand how individual filings relate to the company’s broader strategy and risk profile. Forms 10-K, 10-Q, and 8-K, along with exhibits, provide the primary regulatory record for IRON and are central to in-depth fundamental research.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 4,080 shares of common stock through Merrill Lynch, with an aggregate market value of $243,780.00. The filing shows the shares were acquired in a private placement from the issuer on 05/01/2020 and paid for in cash. The sale is scheduled to occur on or about 08/22/2025 and the shares are listed as traded on Nasdaq. The filer represents they are not aware of any undisclosed material adverse information about the issuer. No securities were reported sold by the filer in the past three months according to the form.
Disc Medicine director Kevin Bitterman reported sales of company common stock under a Rule 10b5-1 plan. The Form 4 shows sales on 08/13/2025 of 24,962 shares at a weighted-average price of $61.15 and on 08/14/2025 of 7,212 shares at a weighted-average price of $60.99, conducted pursuant to a 10b5-1 trading plan dated January 31, 2025. The filing lists substantial indirect holdings attributed to investment vehicles: 600,120 shares following the 08/13 sale and 592,908 shares following the 08/14 sale, plus additional holdings of 420,549 shares and 51,000 shares held by named funds. The report was signed by an attorney-in-fact on 08/15/2025.
Atlas Venture and affiliated funds reported holdings in Disc Medicine, Inc. This Amendment No. 4 to a prior Schedule 13D discloses that multiple Atlas Venture funds collectively beneficially own 2,148,984 shares of Disc Medicine common stock, representing an estimated 6.2% of outstanding shares based on 34,765,581 shares outstanding as of July 31, 2025. Individual fund holdings are reported as Atlas Venture Fund X: 1,084,527 shares (3.1%), Atlas Venture Fund XII: 51,000 shares (0.1%), Atlas Venture Opportunity Fund I: 592,908 shares (1.7%), and Atlas Venture Opportunity Fund II: 420,549 shares (1.2%). The filing states these reporting persons have shared voting and dispositive power over their respective shares and notes they "may be deemed" a group but explicitly disclaim group membership. The amendment references recent transactions in Exhibit 99.1 and updates prior Schedule 13D disclosures.
Disc Medicine, Inc. (IRON) submitted a Form 144 proposing the sale of 7,212 shares of Common Stock through Merrill Lynch, with an aggregate market value of $440,653.20. The filing lists 34,765,581 shares outstanding and an approximate sale date of 08/14/2025 on Nasdaq. The shares were originally acquired in a private placement on 05/01/2020 from the issuer and paid in cash. The filer reports no securities sold in the past three months and includes the standard representation about no undisclosed material information and compliance with Rule 10b5-1 if applicable.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 12,862 shares of common stock through Merrill Lynch One Bryant Park (New York) with an aggregate market value of $785,868.20. The filing states the company has 34,765,581 shares outstanding and lists the approximate sale date as 08/14/2025 on the Nasdaq.
The securities were originally acquired on 05/01/2020 in a private placement from the issuer, paid in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information. The notice includes the usual signature and legal attestation language.
Frazier-affiliated funds disclose their holdings in Disc Medicine (Common Stock, CUSIP 254604101). The largest single holding reported is 1,026,489 shares (3.0% of the class) held directly by Frazier Life Sciences Public Fund, L.P., with shared voting and dispositive power. Other direct holdings include 300,643 shares (0.9%) by Frazier Life Sciences Public Overage Fund, L.P., 264,484 shares (0.8%) by Frazier Life Sciences XI, L.P., and 63,218 shares (0.2%) by Frazier Life Sciences X, L.P.
The filing clarifies governance and attribution: several entities report shared voting and shared dispositive power over these positions and the Statement corrects any prior over-attribution of ownership to certain committee members. Percentages are calculated using 34,634,295 shares outstanding as stated in the filing.
Disc Medicine, Inc. (IRON) filed a Form 144 reporting a proposed sale of 24,962 shares of common stock, with an aggregate market value of $1,473,506.86, to be sold through Merrill Lynch One Bryant Park, New York on Nasdaq with an approximate sale date of 08/13/2025. The filing states the shares were acquired in a private placement from the issuer on 05/01/2020 and paid in cash on that date.
The form also lists multiple sale transactions by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. during July and August 2025, including a sale of 53,215 shares on 07/23/2025 for $3,244,656.91. The filing reports 34,765,581 shares outstanding for the issuer. No signature date or additional issuer relationship details are provided in the extract.
Disc Medicine (IRON) filed a Form 144 proposing the sale of 44,520 shares of common stock with an aggregate market value of $2,628,015.60, to be sold through Merrill Lynch on Nasdaq. The shares were acquired in a private placement on 05/01/2020 and the filing lists an approximate sale date of 08/13/2025. The filing also discloses multiple recent dispositions by Atlas Venture-related funds: a total of 145,916 shares sold in the past three months, generating approximately $8,905,720.24 in gross proceeds. The issuer has 34,765,581 shares outstanding per the form.
Wellington Management and affiliated entities report beneficial ownership of 1,432,090 shares of Disc Medicine, Inc. common stock, representing 4.13% of the class. The filing shows shared voting power over 1,074,282 shares and shared dispositive power over 1,432,090 shares; sole voting and dispositive powers are reported as 0. The securities are owned of record by clients of the listed Wellington investment advisers and are held in the ordinary course of business. The filing identifies Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP as reporting entities and lists the relevant Wellington investment adviser subsidiaries that manage the client accounts holding these shares.